The 2010 annual meeting of the American Academy of Neurology (AAN) is being held in Toronto April 10-17.
As presentations are given at the meeting, MDA will be posting articles highlighting neuromuscular disease research of particular interest to the MDA community. Check this site regularly for updates.
Established in 1948, the AAN is an international professional association of more than 22,000 neurologists and neuroscience professionals “dedicated to providing the best possible care for patients with neurological disorders.” Some 10,000 members are expected to attend this week-long event, at which neurologist Valerie Cwik, MDA Medical Director and Executive Vice President for Research, will represent MDA.
Many of the hundreds of presenters at the AAN meeting have submitted abstracts (summaries) of their work, which can be viewed online on the science pages of the AAN site. (Note: Registration is required.)
On Tuesday, April 13, MDA will post articles about three presentations from the meeting: gene therapy in Duchenne muscular dystrophy (DMD); trials of lithium as a treatment for amyotrophic lateral sclerosis (ALS); and trials of an experimental drug to treat unwanted laughing/crying spells in ALS.
On Wednesday, April 14, MDA will report on presentations of trials of two experimental treatments for DMD: exon skipping and stop-codon read-through.
Friday, April 16, will see a report of PTC Therapeutics’ AAN presentation, giving further information about the trial of its experimental stop-codon read-through drug ataluren.
Check back for AAN updates as they become available.